Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Tecentriq Hybreza, atezolizumab/hyaluronidase-tqjs
Synonyms :
atezolizumab/hyaluronidase-tqjs
Class :
PD-1/PD-L1 Inhibitors
Brand Name :
Tecentriq Hybreza, atezolizumab/hyaluronidase-tqjs
Synonyms :
atezolizumab/hyaluronidase-tqjs
Class :
PD-1/PD-L1 Inhibitors
Adult
Solution
1875mg/15ml
As adjuvant therapy:
Administer dose of 15 ml through subcutaneous route for every 3 weeks up to 12 months
As first-line treatment for metastatic disease:
Administer dose of 15 ml through subcutaneous route for every 3 weeks
Administer dose of 15 ml through subcutaneous route every 3 weeks with carboplatin and etoposide for every 21 days up to 4 cycles
Administer dose of 15 ml through subcutaneous route every 3 weeks with bevacizumab dose of 15 mg/kg intravenously for every 3 weeks
Not determined
Atezolizumab is a monoclonal antibody that targets on PD-L1 inhibitors. It inhibits PD-L1 interaction with PD-1 and B7.1 receptors on T cells to prevent immune evasion.
Hyaluronidase injection increase the penetration of other substances in extracellular space to improve effectiveness.
Frequency defined:
>50%
Decreased hemoglobin
>10-50%
All grades
Decreased sodium
Decreased lymphocytes
Decreased calcium
Increased potassium
Increased calcium
Anti-atezolizumab antibodies
Fatigue
Decreased albumin
Increased alkaline phosphatase
Increased AST/ALT
Increased creatinine
Musculoskeletal pain
Cough
Dyspnea
Decreased appetite
1-10%
All grades
Immune-mediated hypothyroidism
Pyrexia
Immune-mediated hepatitis
Local injection site reactions
Immune-mediated pneumonitis
Grade 3 or 4
Decreased lymphocytes
Decreased sodium
Decreased calcium
Increased AST/ALT
Increased calcium
Decreased albumin
Increased INR
Increased potassium
Increased creatinine
Increased alkaline phosphatase
<1%
All grades
Immune-mediated hypophysitis
Immune-mediated adrenal insufficiency
Immune-mediated thyroiditis
Grade 3 or 4
Fatigue
Musculoskeletal pain
Immune-mediated hepatitis
Drug interaction:
There is no significant drug interaction.
None
Contraindications:
Hypersensitivity
Cautions:
Immune-mediated adverse reactions
Embryo-fetal toxicity
Infusion-related reactions
Allogeneic hematopoietic stem cell transplantation complications
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
T cells are reactivated to recognize and attack on tumor cells. The higher immune response increases T cell infiltration and cytotoxic effects on tumors.
Hyaluronidase breaks hyaluronic acid at glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid.
Pharmacodynamics:
The treatment leads to improved anti-tumor immunity, which reduce tumor size in different cancers based on tumor cell PD-L1 expression.
Hyaluronidase improves distribution which breaks down hyaluronic acid at injection site to enhance absorption.
Pharmacokinetic:
Absorption:
It has bioavailability up to 72% with SC route.
Distribution:
The Steady-state volume of distribution is 6.9 L for IV route.
Metabolism:
It is not metabolized with cytochrome P450 enzymes pathways.
Excretion and elimination:
It has half-life of 27 days and clearance up to 0.2 L daily for IV route.
It is administered through subcutaneous route.
Generic Name: atezolizumab/hyaluronidase-tqjs
Why do we use atezolizumab/hyaluronidase-tqjs?
Atezolizumab/hyaluronidase-tqjs is a combination drug used in treatment of both types of cell lung cancers including non and small.
It is indicated in treatment of hepatocellular carcinoma i.e., liver cancer.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
